GWM
VKTX icon

Geneos Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Geneos Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-440
Closed -$1K – 2593
2022
Q2 		$1K Hold
440
– – ﹤0.01% 2550
2022
Q1 		$1K Hold
440
– – ﹤0.01% 2707
2021
Q4 		$2K Hold
440
– – ﹤0.01% 2616
2021
Q3 		$2K Hold
440
– – ﹤0.01% 2678
2021
Q2 		$2K Sell
440
-1,910
-81% -$11.3K ﹤0.01% 2695
2021
Q1 		$15K Hold
2,350
– – ﹤0.01% 2218
2020
Q4 		$2K Buy
2,350
+1,975
+527% +$12K ﹤0.01% 2732
2020
Q3 		$2K Hold
375
– – ﹤0.01% 2455
2020
Q2 		$2K Buy
+375
New +$2.49K ﹤0.01% 2393

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geneos Wealth Management's VKTX Position: Q3 2022 in Review

Geneos Wealth Management sold out of Viking Therapeutics (VKTX) in Q3 2022, closing a stake of 440 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in VKTX in Q2 2020 and held it in 9 quarters. The position peaked at $15K in Q1 2021. 107 funds tracked by Wall St. Rank hold VKTX as of Q3 2022.

  • Geneos Wealth Management reported no remaining Viking Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 440 Viking Therapeutics shares in Q3 2022, an estimated $1K.
  • Geneos Wealth Management first reported a position in Viking Therapeutics in Q2 2020 and held it in 9 quarters.
  • Geneos Wealth Management's Viking Therapeutics position peaked at $15K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.